Equity Details
Price & Market Data
Price: $1.71
Daily Change: -$0.02 / 1.17%
Daily Range: $1.71 - $1.73
Market Cap: $130,606,562
Daily Volume: 1,000
Performance Metrics
1 Week: -1.16%
1 Month: -1.16%
3 Months: -0.96%
6 Months: -0.96%
1 Year: 189.8%
YTD: -1.16%
About Helix BioPharma Corp. (HBPCF)
A financial summary of Helix BioPharma Corp. (HBPCF). Price: 1.71, daily change: -$0.02 / 1.17%. Market cap: 130,606,562. Performance from 3-month to 1-year.
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Canada
Details
Helix BioPharma Corp. a clinical-stage biopharmaceutical company developing therapies in the field of immune-oncology in Canada. Its product pipeline comprises L-DOS47, a clinical-stage antibody-enzyme conjugate (AEC) that neutralizes the microenvironment of solid tumors; LDOS001, which is in phase I clinical trial to treat non-small cell lung cancer; LDOS002, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer; LDOS003, which is in phase II clinical trial to treat non-small cell lung cancer; LDOS006, which is in phase Ib/II for the treatment of pancreatic cancer; and LDOS007, which is in phase Ib/II for the treatment of lung cancer. It develops V-DOS47, an antibody-DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor. It has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging. The company has an agreement with metaShape Pharma AG for covering LEUMUNA, within the field of adipose tissue-related and metabolic diseases. Helix BioPharma Corp. was incorporated in 2008 and is headquartered in Vancouver, Canada.